61576
document
Pimecrolimus cream and Tacrolimus ointment in the treatment of atopic dermatitis : a pilot study on patient preference . BACKGROUND Pimecrolimus cream 1 % is approved for mild to moderate atopic dermatitis in children older than two years of age and adults . Tacrolimus ointment 0.03 % is approved for moderate to severe atopic dermatitis in the patient population between two to seventeen years of age and Tacrolimus 0.1 % ointment for moderate to severe atopic dermatitis in patients 18 years of age and older . However , beyond safety and efficacy , the delivery system or vehicle used in topical treatment formulations is equally important in affecting patient satisfaction , tolerability , and subsequent treatment compliance and hence clinical resolution of active disease .
61577
Intervention_Pharmacological
Pimecrolimus cream
61578
Intervention_Pharmacological
Tacrolimus ointment
61579
Intervention_Pharmacological
Pimecrolimus
61580
Intervention_Pharmacological
Tacrolimus ointment
61581
Intervention_Pharmacological
Tacrolimus 0.1 % ointment
61582
Outcome_Physical
atopic dermatitis :
61583
Outcome_Other
safety and efficacy
61584
Outcome_Other
patient satisfaction , tolerability , and subsequent treatment compliance
61585
Outcome_Other
clinical resolution
61586
Participant_Condition
atopic dermatitis
61587
Participant_Condition
atopic dermatitis
61588
Participant_Age
children older than two years of age
61589
Participant_Age
adults
61590
Participant_Condition
atopic dermatitis
61591
Participant_Age
two to seventeen years of age
61592
Participant_Condition
severe atopic dermatitis
61593
Participant_Age
18 years of age and older